Targeting TRIM25 as a therapeutic strategy to enhance ferroptosis in glioblastoma cells.

ABSTRACT:

Background

Glioblastoma (GBM) is the most common malignant brain tumor with a dismal prognosis (< 7% 5-year survival) under current first-line treatment. While inducing programmed cell death (PCD) is a promising antitumor strategy, its effectiveness in GBM remains controversial. Ferroptosis emerged as the most enriched PCD process and was highly correlated with GBM malignant progression.

Methods

We performed a CRISPR-Cas9 loss-of-function screen to identify critical ferroptosis contributors. Mechanistic studies involved assessing mitochondrial function and morphology. Protein interaction and degradation pathways were investigated using immunoprecipitation and ubiquitination assays. We developed a blood-brain-barrier-penetrating genome editing delivery system, Angiopep-2-modi

SUBMITTER: Zhu M 

PROVIDER: S-EPMC12781578 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature